Retatrutide, explained: the triple-agonist being studied for weight loss

Retatrutide is not FDA-approved^[4]. It is investigational — still in clinical trials, not available by prescription, and not something GHC offers yet. We're writing about it early because men keep asking, and because the early trial data is genuinely interesting — so that if it does clear the FDA, this is the page you'll already trust. Retatrutide is a triple agonist, meaning it acts on three metabolic receptors at once^[1]. This article walks through what the research actually shows, without hype and without promises.

What is retatrutide?

Retatrutide is the first triple agonist acting on GLP-1, GIP, and glucagon receptors with published Phase 2 data in people with obesity as well as in people with type 2 diabetes (Goldney et al., Current Cardiovascular Risk Reports, 2025). It's an investigational injectable from Eli Lilly^[3], and it stays investigational until the trials and the FDA say otherwise.

Is retatrutide available yet?

Not yet. Retatrutide is not FDA-approved. It's still in clinical trials, which means no regulated channel can legitimately dispense it to you today, and anything sold as "retatrutide" right now reaches you through an unregulated channel — outside the trials and outside FDA oversight. GHC doesn't offer, prescribe, or compound retatrutide yet. If the FDA ever approves it, we'll update this page with what the label actually says. For now, we're reporting on the research, not selling anything.

How does retatrutide compare to tirzepatide?

Carefully — and not as a ranking. A 2025 systematic review and network meta-analysis of dual and triple incretin agonists in type 2 diabetes care — retatrutide and tirzepatide among them — leaned in part on indirect comparisons and concluded that direct head-to-head trials are needed to confirm its results (Yan et al., Acta Diabetologica, 2025). So we won't hand you a retatrutide vs tirzepatide ranking — that's the researchers' own caveat, not just ours. Tirzepatide (Zepbound®) is a dual GLP-1/GIP receptor agonist, FDA-approved for chronic weight management in adults with obesity, or with overweight plus a weight-related condition^[7]. Retatrutide adds a third receptor — glucagon — on top of those two, and it is still being tested (Goldney et al., Current Cardiovascular Risk Reports, 2025). Tirzepatide is approved and available; retatrutide is not. Individual results vary.

What did the retatrutide trials show?

In the published Phase 2 data, retatrutide achieved up to 24.2% mean weight loss after 48 weeks in people with obesity^[8], and 16.9% in people with type 2 diabetes after 36 weeks^[9] (Goldney et al., Current Cardiovascular Risk Reports, 2025). Retatrutide also reduced hepatic steatosis — liver fat — by 82%^[10] (Goldney et al., 2025). These are early findings from mid-stage studies. A comprehensive Phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular and renal outcomes, and results can change as more data comes in. Individual results vary.

What should men know about retatrutide?

For men weighing their options, the practical takeaway is that retatrutide for men is not a real-world choice today — it's a research story worth watching, not a treatment you can start. If weight management is the goal now, the conversation should center on approved, available options and on protecting lean mass. Our overview of GLP-1 for men covers the muscle-first approach that matters when appetite drops fast.

Why the triple-agonist mechanism gets attention

GLP-1 receptor agonists have already transformed obesity and type 2 diabetes management, and tirzepatide's dual GLP-1/GIP action paved the way for the next generation. Among those, triple agonists like retatrutide — targeting GLP-1, GIP, and glucagon receptors — represent a promising next step, and retatrutide is the most advanced candidate in that retatrutide weight loss research (Goldney et al., Current Cardiovascular Risk Reports, 2025). But mechanism is not outcome — a promising target still has to clear large, long-term trials before anyone can say it's both effective and safe for everyday use.

The side-effect picture, honestly

No drug in this class is side-effect-free, and retatrutide is no exception. Gastrointestinal symptoms were the most common side effects with retatrutide^[12]. That's a mid-stage read: a comprehensive Phase 3 program is ongoing to evaluate retatrutide's efficacy, safety, and cardiovascular and renal outcomes (Goldney et al., 2025). Retatrutide remains investigational until those trials report. If you're weighing retatrutide side effects against a drug you could actually start today, that's the comparison worth having with a licensed medical provider.

What to do while it's still investigational

If you're serious about metabolic health now, focus on what's real: an evaluation with a licensed medical provider, honest lab work, and approved treatments where clinically appropriate. You can explore our weight management resources for how that process works. Retatrutide may or may not join the toolkit years from now — but chasing an unapproved drug through unverified sellers is a genuine risk, not a shortcut.

FAQ

Is retatrutide the same as Ozempic or tirzepatide?

No. Semaglutide (Ozempic®/Wegovy®, Novo Nordisk) is a single GLP-1 agonist^[13]. Tirzepatide (Zepbound®, Eli Lilly) is a dual GLP-1/GIP receptor agonist, FDA-approved for chronic weight management in adults with obesity, or with overweight plus a weight-related condition. Retatrutide is an investigational triple agonist that adds the glucagon receptor^[14] — a different, not-yet-approved drug.

Can I get a prescription for retatrutide?

Not yet. Retatrutide is not FDA-approved, so it isn't legally available by prescription today, and GHC doesn't offer it yet. Any source claiming to sell retatrutide right now is operating outside verified, regulated channels. If it clears the FDA, we'll update this page with what the label says.

How much weight did people lose on retatrutide in trials?

In the published Phase 2 data, retatrutide achieved up to 24.2% mean weight loss after 48 weeks in people with obesity, and 16.9% in people with type 2 diabetes after 36 weeks (Goldney et al., Current Cardiovascular Risk Reports, 2025). These are early trial averages, not guarantees, and larger Phase 3 studies are still underway. Individual results vary.

Is retatrutide safe?

That question isn't settled yet. Gastrointestinal symptoms were the most common side effects with retatrutide. A comprehensive Phase 3 program is ongoing to evaluate retatrutide's efficacy, safety, and cardiovascular and renal outcomes (Goldney et al., 2025). Only completed, reviewed trials and FDA evaluation can answer the safety question fully.

When might retatrutide be approved?

There's no confirmed date. Phase 3 trials are ongoing, and approval — if it happens — depends on those results and FDA review. We report on the science and don't speculate on timelines.

Gentlemen's Health Collective operates under exclusive partnership with an independent network of licensed medical providers. All medical decisions are made by your assigned, licensed medical provider. Medications are dispensed through partnered pharmacies licensed in your state. Not all treatments are appropriate for all patients. Treatment availability varies by state. This article is for general information and is not medical advice. Talk to a licensed medical provider about your situation. Individual results vary. Ozempic®/Wegovy® are trademarks of Novo Nordisk; Mounjaro®/Zepbound® are trademarks of Eli Lilly. Retatrutide is investigational and not yet FDA-approved or offered by GHC.